RemeGen’s Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China’s NMPA
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that the Center...
Drug
AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China
AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568)’s co-developed antibody drug conjugate (ADC), Enhertu (trastuzumab...
BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
On October 14, 2024, Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the National Medical Products...
Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia
Sichuan Biokin Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed on the Shanghai Stock Exchange...
BrightGene’s BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes
BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166), a Chinese biopharmaceutical company, has announced positive results...
Dizal Pharmaceutical’s Sunvozertinib Earns Breakthrough Designation for NSCLC from China’s NMPA
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has announced that...
Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment
Reforgene Medicine, a pioneer in gene editing therapy based in Guangzhou, has secured Investigational New...
Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed as...
Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
The Center for Drug Evaluation (CDE) has indicated that Novartis (NYSE: NVS), the Swiss pharmaceutical...
Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study
Pfizer Inc. (NYSE: PFE) has announced positive topline results regarding overall survival (OS) in the...
CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has initiated...
KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China
KangaBio, a biopharmaceutical company based in Shanghai, has announced that its investigational new drug (IND)...
Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials
JNJ-78278343, a KLK2-CD3 bispecific antibody, is currently in Phase I clinical trials globally. According to...
Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area
Merck KGaA (MRK, NYSE: MRK) , a leading science and technology company based in Germany,...
Junshi Biosciences’ Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment
Junshi Biosciences (HKG: 1877; SHA: 688180), a leading biopharmaceutical company in China, has announced that...
Juventas Cell Therapy’s CAR-T Therapy Clears for SLE-ITP Study in China
The China Center for Drug Evaluation (CDE) has given the green light for a study...
Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...
Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B
Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...